Ehrlichiosis and anaplasmosis

Infections in Medicine

Volumn 21, Issue 9, 2004, Pages 433-451

  Bakken, Johan S ^a,b   Dumler, J Stephen ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b St Luke's Hospital   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplasmosis; Ehrlichiosis; Tick borne infection

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; DOXYCYCLINE HYCLATE; LEVOFLOXACIN; RIFAMPICIN; TROVAFLOXACIN;

ANAPLASMA; ANAPLASMOSIS; ANTIBIOTIC THERAPY; ARTICLE; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; EHRLICHIA; EHRLICHIOSIS; FATALITY; FEVER; HEADACHE; HUMAN; IMMUNOFLUORESCENCE TEST; MYALGIA; NONHUMAN; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RICKETTSIA; SEROLOGY; TICK BORNE DISEASE;

EID: 5144234714     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and " HGE agent" as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol. 2001;51(pt 6):2145-2165.
2. International Classification of Diseases, Ninth Revision, Clinical Modification [6th]. 2002. PMIC, Los Angeles. Available at: http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm. Accessed August 12, 2004.
3. Dumler JS, Walker DH. Tick-borne ehrlichioses. Lancet Infect Dis. 2001;1:21-28.
4. Bakken JS, Dumler JS, Chen SM, et al. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA. 1994;272:212-218.
5. Maeda K, Markowitz N, Hawley RC, et al. Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med. 1987;316:853-856.
6. Mott J Barnewall RE, Rikihisa Y. Human granulocytic ehrlichiosis agent and Ehrlichia chaffeensis reside in different cytoplasmic compartments in HL-60 cells. Infect Immun. 1999;67: 1368-1378.
7. Webster P, IJdo JW, Chicoine LM, Fikrig E. The agent of human granulocytic ehrlichiosis resides in an endosomal compartment. J Clin Invest. 1998;101:1932-1941.
8. Anderson BE, Dawson JE, Jones DC, Wilson KH. Ehrlichia chaffeensis, a new species associated with human ehrlichiosis. J Clin Microbiol. 1991;29:2838-2842.
9. Fishbein DB, Sawyer LA, Holland CJ, et al. Unexplained febrile illnesses after exposure to ticks. Infection with an Ehrlichia? JAMA. 1987; 257:3100-3104.
10. Dumler JS, Asanovich KM, Bakken JS, et al. Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic Ehrlichia. J Clin Microbiol. 1995;33:1098-1103,
11. Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, et al. Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med. 1996;125:904-908.
12. Bakken JS, Dumler JS. Human granulocytic ehrlichiosis in the United States Infect Med. 1996;10:877-912.
13. Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med. 1999;341:148-155.
14. Paddock CD, Folk SM, Shore GM, et al. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis. 2001;33: 1586-1594.
15. Anderson JF. The natural history of ticks. Med Clin North Am. 2002;86:205-218.
16. Dumler JS, Bakken JS. Ehrlichial diseases of humans: emerging tick-borne infections. Clin Infect Dis. 1995;20:1102-1110.
17. Olano JP, Masters E, Hogrefe W, Walker DH. Human monocytotropic ehrlichiosis, Missouri. Emerg Infect Dis. 2003;9:1579-1586.
18. Fishbein DB, Dawson JE, Robinson LE. Human ehrlichiosis in the United States, 1985 to 1990. Ann Intern Med. 1994;120:736-743.
19. Gardner SL, Holman RC, Krebs JW, et al. National surveillance for the human ehrlichioses in the United States, 1997-2001, and proposed methods for evaluation of data quality. Ann N Y Acad Sci. 2003;990:80-89.
20. Groseclose SL, Brathwaite WS, Hall PA, et al. Summary of notifiable diseases - United States, 2002. MMWR. 2004;51:1-84.
21. McQuiston JH, Paddock CD, Holman RC, Childs JE. The human ehrlichioses in the United States. Emerg Infect Dis. 1999;5:635-642.
22. Fritz CL, Kjemtrup AM, Conrad PA, et al. Seroepidemiology of emerging tickborne infectious diseases in a Northern California community. J Infect Dis. 1997;175:1432-1439.
23. Petersen LR, Sawyer LA, Fishbein DB, et al. An outbreak of ehrlichiosis in members of an Army Reserve unit exposed to ticks. J Infect Dis. 1989;159:562-568.
24. Standaert SM, Dawson JE, Schaffner W, et al. Ehrlichiosis in a golf oriented retirement community. N Engl J Med. 1995;333:420-425.
25. Olano JP, Walker DH. Human ehrlichioses. Med Clin North Am. 2002;86:375-392.
26. Everett ED, Evans KA, Henry RB, McDonald G. Human ehrlichiosis in adults after tick exposure. Diagnosis using polymerase chain reaction. Ann Intern Med. 1994;120:730-735.
27. Dumler JS, Sutker WL, Walker DH. Persistent infection with Ehrlichia chaffeensis. Clin Infect Dis. 1993;17:903-905.
28. Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev. 2003;16:37-64.
29. Marty AM, Dumler JS, Imes G, et al. Ehrlichiosis mimicking thrombotic thrombocytopenic purpura. Case report and pathological correlation. Hum Pathol. 1995;26:920-925.
30. McKechnie DB, Slater KS, Childs JE, et al. Survival of Ehrlichia chafteensis in refrigerated, ADSOL-treated RBCs. Transfusion. 2000;40: 1041-1047.
31. McQuiston JH, Childs JE, Chamberland ME, Tabor E. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States [published correction appears in Transfusion. 2000;40:891]. Transfusion. 2000;40:274-284.
32. Standaert SM, Yu T, Scott MA, et al. Primary isolation of Ehrlichia chaffeensis from patients with febrile illnesses: clinical and molecular characteristics. J Infect Dis. 2000;181:1982-1088.
33. Olano JP, Hogrefe W, Seaton B, Walker DH. Clinical manifestations, epidemiology, and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting. Clin Diagn Lab Immunol. 2003;10:891-896.
34. Dumler JS, Dawson JE, Walker DH. Human ehrlichiosis: hematopathology and imumnohistologic detection of Ehrlichia chaffeensis. Hum Pathol. 1993;24:391-396.
35. Sehdev AE, Dumler JS. Hepatic pathology in human monocytic ehrlichiosis. Ehrlichia chaffeensis infection. Am J Clin Pathol. 2003;119:859-865.
36. Barnewall RE, Ohashi N, Rikihisa Y. Ehrlichia chaffeensis and E. sennetsu, but not the human granulocytic ehrlichiosis agent, colocalize with transferrin receptor and up-regulate transferrin receptor mRNA by activating iron-responsive protein 1. Infect Immun. 1999;67:2258-2265.
37. Barnewall RE, Rikihisa Y. Abrogation of gamma interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with iron-transferrin. Infect Immun. 1994;62:4804-4810.
38. Ismail N, Soong L, McBride JW et al. Overproduction of TNF-alpha by CD8+type 1 cells and down-regulation of IFN-gamma production by CD4+ Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichiosis. J Immunol. 2004;172:1786-1800.
39. Park J, Choi KS, Grab DJ, Dumler JS. Divergent interactions of Ehrlichia chaffeensis- and Anaplasma phagocytophilum-infected leukocytes with endothelial cell barriers. Infect Immun. 2003;71: 6728-6733.
40. Bakken JS, Dumler JS. Human granulocytic ehrlichiosis. Clin Infect Dis. 2000;31:554-560.
41. Krause PJ, McKay K, Thompson CA, et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis. 2002;34:1184-1191.
42. Castro MB, Nicholson WL, Kramer VL, Childs JE. Persistent infection in Neotoma fuscipes (Muridae: Sigmodontinae) with Ehrlichia phagocytophila sensu lato. Am J Trop Med Hyg. 2001; 65:261-267.
43. Telford SR 3rd, Dawson JE, Katavolos P, et al. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc Natl Acad Sci U S A. 1996;93:6209-6214.
44. Katavolos P, Armstrong PM, Dawson JE, Telford SR 3rd. Duration of tick attachment required for transmission of granulocytic ehrlichiosis. J Infect Dis. 1998;177:1422-1425.
45. Aguero-Rosenfeld ME, Donnarumma. L, Zentmaier L, et al. Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol. 2002;40:2612-2615.
46. Bakken JS, Goellner F, Van Etten M, et al. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin Infect Dis. 1998;27:1491-1496.
47. Hilton E DeVoti J, Benach JL et al. Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States. Am J Med. 1999;106:404-409.
48. Woessner R, Gaertner BC, Grauer MT, et al. Incidence and prevalence of infection with human granulocytic ehrlichiosis agent in Germany. A prospective study in young healthy subjects. Infection. 2001;29:271-273.
49. Bakken JS, Haller I, Riddell D, et al. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis. 2002;34:22-27.
50. Bakken JS, Krueth J, Wilson-Nordskog C, et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA. 1996;275: 199-205.
51. Bakken JS, Dumler JS. Ehrlichia and Anaplasma species. In: Yu V, Weber R, Raoult D, eds. Antimicrobial Therapy and Vaccine. New York: Apple Trees Productions, LLC; 2002:875-882.
52. Cizman M, Avsic-Zupanc T, Petrovec M, et al. Seroprevalence of ehrlichiosis, Lyme borreliosis and tick-borne encephalitis infections in children and young adults in Slovenia. Wien Klin Wochenschr. 2000;112:842-845.
53. Leiby DA, Chung AP, Cable RG, et al. Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors. Transfusion. 2002;42:1585-1591.
54. Bakken JS, Tilden RL, Walls JJ, Dumler JS. Influence of Occupation, Preexisting Illness, and Chronic Medication Use on the Severity of Chronic Granulocytic Ehrlichiosis. Marseilles, France: Elsevier; 1999:195-198.
55. Bakken JS, Erlemeyer SA, Kanoff RJ, et al. Demyelinating polyneuropathy associated with human granulocytic ehrlichiosis. Clin Infect Dis. 1998;27:1323-1324.
56. Horowitz HW, Marks SJ, Weintraub M, Dumler JS. Brachial plexopathy associated with human granulocytic ehrlichiosis. Neurology. 1996;46: 1026-1029.
57. Jahangir A, Kolbert C, Edwards W, et al. Fatal pancarditis associated with human granulocytic ehrlichiosis in a 44-year-old man. Clin Infect Dis. 1998;27:1424-1427.
58. Lepidi H, Bunnell JE, Martin ME, et al. Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg. 2000;62:29-37.
59. Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis. 2001;32:862-870.
60. Massung RF, Slater KG. Comparison of PCR assays for detection of the agent of human granulocytic ehrlichiosis, Anaplasma phagocytophilum. J Clin Microbiol. 2003;41:717-722.
61. Goodman JL, Nelson C, Vitale B, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis [published correction appears in N Engl J Med. 1996; 335: 361]. N Engl J Med. 1996;334:209-215.
62. Aguero-Rosenfeld ME. Diagnosis of human granulocytic ehrlichiosis: state of the art. Vector Borne Zoonotic Dis, 2002;2:233-239.
63. Belongia EA, Reed KD, Mitchell PD, et al. Tickborne infections as a cause of nonspecific febrile illness in Wisconsin. Clin Infect Dis. 2001; 32:1434-1439.
64. Walls JJ, Aguero-Rosenfeld M, Bakken JS, et al. Inter-and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test. J Clin Microbiol. 1999;37:2968-2973.
65. Dumler JS, Trigiani ER, Bakken JS, et al. Serum cytokine responses during acute human granulocytic ehrlichiosis. Clin Diagn Lab Immunol. 2000;7:6-8.
66. Martin ME, Caspersen K, Dumler JS. Immunopathology and ehrlichial propagation are regulated by interferon-gamma and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol. 2001;158:1881-1888.
67. Choi KS, Garyu J, Park J, Dumler JS. Diminished adhesion of Anaplasma phagocytophilum-infected neutrophils to endothelial cells is associated with reduced expression of leukocyte surface selectin. Infect Immun. 2003;71:4586-4594.
68. Horowitz HW, Hsieh TC, Aguero-Rosenfeld ME, et al. Antimicrobial susceptibility of Ehrlichia phagocytophila. Antimicrob Agents Chemother. 2001;45:786-788.
69. Klein MB, Nelson CM, Goodman JL. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother. 1997;41:76-79.
70. Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother. 2003;47:413-415.
71. Ehrlichia infections (human ehrlichioses). In: Pickering LK, ed. Red Book: 2003 Report of the Committee of Infectious Diseases. Elk Grove Village, III: American Academy of Pediatrics; 2003: 266-269.
72. Tetracyclines. In: McEvoy GK, ed. AHFS Drug Information. Bethesda, Md: American Society of Health-System Pharmacists; 2004:433-457.
73. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother. 1992;36:2799-2803.
74. Buitrago MI, IJdo JW, Rinaudo P, et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis. 1998;27:213-215.
75. Elston DM. Perinatal transmission of human granulocytic ehrlichiosis. N Engl J Med. 1998; 339:1941-1942.
76. Krause PJ, Corrow CL, Bakken JS. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. Pediatrics. 2003;112(3, pt 1):e252-e253.
77. Walker DH, Bakken JS, Brouqui P, et al. Diagnosing human ehrlichioses: current status and recommendations. Am Soc Microbiol News. 2000;5:287-293.